

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				SERIAL NO. 10/535228			
				FILING DATE Concurrently Herewith			
				APPLICANT Boggs et al.			
				GROUP 1626			
				EXAMINER NOLAN, JASON			
				ATTORNEY DOCKET NO. PU5028USW			
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
Continue on page _____							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
D		WO 00/37077	June 29, 2000	WIPO			
J		WO 03/015771	Feb. 27, 2003	WIPO			
Continue on page _____							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
Continue on page _____							
EXAMINER JNL					DATE CONSIDERED 2-27-2007		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

Sheet 1 of 2

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY DOCKET NO. PU5028USW	SERIAL NO. 10/635,228
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT BOGGS, et al.	
		FILING DATE May 17, 2005	GROUP Not designated 1626

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
<i>DMW</i>	1.	US-6167797-B1	02-13-2001	Pruitt et al.			
<i>DMW</i>	2.	US-6187814-B1	02-13-2001	Elias et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes No	
<i>DMW</i>	3.	EP-312657-A1	04-28-1989	EP				
<i>DMW</i>	4.	GB-2293360-A	03-27-1998	GB				
<i>DMW</i>	5.	WO-2000/59902-A	10-12-2000	WO				
<i>DMW</i>	6.	WO-2000/84876-A	11-02-2000	WO				
<i>DMW</i>	7.	WO-2001/019778-A1	03-22-2001	WO				
<i>DMW</i>	8.	WO-98/57931-A	12-23-1998	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc)

<i>DMW</i>	9.	BM FORMAN, ET AL.; Identification of a nuclear receptor (that is activated by farnesol metabolites); Cell; 1995; 81; 687-693;
<i>DMW</i>	10.	DJ MANGELSDORF, ET AL.; The RXR heterodimers and orphan receptors; Cell; 1995; 83; 841-850;
<i>DMW</i>	11.	DW RUSSELL, ET AL.; Nuclear Orphan Receptors Control Cholesterol Catabolism; Cell; 1999; 97; 539-542;
<i>DMW</i>	12.	HOFMANN, AF; The Continuing Importance of Bile Acids in Liver and Intestinal Disease; Arch Intern Med; 1999; 159; 2647-2656;
<i>DMW</i>	13.	MALONEY, P. ET AL.; Identification of a Chemical Tool for the Orphan Nuclear Receptor FXR; J Med Chem; 2000; 43/16; 2971-2974;
<i>DMW</i>	14.	NEUBERGER J; Primary Biliary Cirrhosis; Lancet; 1997; 350; 875-879;

Examiner Signature <i>[Signature]</i>	Date Considered 2-27-2007
EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Sheet 2 of 2

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY DOCKET NO. PU5028USW	SERIAL NO. 10/535,228
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT BOGGS, et al	
		FILING DATE May 17, 2005	GROUP <i>Reassigned</i> 1626

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation Yes No
<i>HW</i> 15.	WO-2001/025210-A2	04-12-2001	WO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc)

<i>HW</i> 16.	SINAL, ET AL.; Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis; Cell; 2000; 102/8; 731-744;
<i>HW</i> 17.	W SEOL, ET AL.; Isolation of proteins that interact specifically with the retinoid X receptor, two novel orphan receptors; Mol Endocrinol; 1995; 9; 72-85;

Examiner Signature <i>[Signature]</i>	Date Considered 2-27-2007
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	